Sirolimus for Kaposi's sarcoma.
The risk of Kaposi's sarcoma (KS) is increased after organ transplantation. Management of KS in the cardiac transplant population may be difficult because reduction of immunosuppression is often not practical. This report describes a case of KS occurring in the early post-transplant period. Modification of immunosuppression with the use of sirolimus led to tumor regression for 24 months, but with subsequent localized progression of disease.
Wasywich
Cara A
CA
Green Lane Cardiovascular Service, Auckland District Health Board, Auckland, New Zealand. caraw@adhb.govt.nz
Croxson
Margaret C
MC
van Doornum
Gerard J
GJ
Coverdale
H Arthur
HA
Ruygrok
Peter N
PN
D000328:Adult; D016027:Heart Transplantation; D019288:Herpesvirus 8, Human; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D017202:Myocardial Ischemia / Q000601:surgery; D011184:Postoperative Period; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D020123:Sirolimus